Vaccines ready for 50 million in Africa's 'Meningitis Belt'

October 4, 2012

A huge vaccination campaign to protect 50 million people against meningitis has been launched in seven African countries aiming to stamp out the deadly virus, health officials said Thursday.

The so-called ' Belt' countries—Benin, Cameroon, Chad, Ghana, Nigeria, Senegal and Sudan—are to get the jabs to ensure "a dramatic impact across the continent," said Seth Berkley, managing director of GAVI (Global Alliance for Vaccines and Immunisation), the group backed by Microsoft tycoon .

"We've known for a long time that there are terrible epidemics of meningitis every five to seven years in the 'Meningitis Belt'," Berkley told reporters in Geneva.

"Nobody really understands why, but there are hundreds of thousands of cases, if not millions."

Meningitis can kill within 48 hours and cause brain damage, hearing loss or in 20 percent of sufferers, GAVI said.

The vaccine, produced in association with the Serum Institute of India and the Bill & Melinda Gates Foundation, was previously used in Burkina Faso where it led to the eradication of the disease after a year, Berkley said.

Just as important, he added, the lack of disease meant that economic development could continue in developing countries, whereas previous epidemics tended to stop trade in its tracks.

"People would avoid getting together, and for those who didn't die you ended up with children with and brain abcesses and all kinds of problems," he said, adding that a child dies from a vaccine-preventable disease every 20 seconds.

The three-month project, due to run until the end of the year, is part of a wider plan to cover 26 .

The aim is to cover everyone from babies to young adults up to age 29, GAVI said in a statement. It also said it plans to immunise around 250 million children by 2015 for a range of illnesses and prevent more than 3.9 million deaths.

In total, GAVI's remit covers 73 countries.

Since its establishment in 2000, GAVI has vaccinated 325 million children and prevented more than five million deaths, it claimed.

Working with pharmaceutical companies and public partners, GAVI also helped develop a new vaccine—HPV—against cervical cancer which causes 275,000 deaths a year, one of the largest killers of women in the developed world, Berkley said.

In China, he added, GAVI coordinated a hepatitis B immunisation programme to prevent liver cancer, responsible for about 325,000 deaths a year, owing to the high rate of transmission of the virus from mother to child.

"Over the next decade those cancer deaths will disappear," he said.

The public private partnership made it possible to "shape the market" for vaccines Berkley said, adding that the GAVI system had brought down prices by "as much as a 90 percent".

Explore further: Partnership sees cervical vaccines for poorer countries

Related Stories

Partnership sees cervical vaccines for poorer countries

November 17, 2011
A major campaigner in vaccines for poorer countries announced plans on Thursday for innoculating up to two million women and girls against cervical cancer by 2015.

Waging war against rotavirus

April 10, 2012
Canada should show leadership in supporting adoption of the rotavirus vaccination in developing countries, but it must also ensure that all Canadian infants are vaccinated against the virus, states an editorial in CMAJ (Canadian ...

New studies show progress, value in vaccination against deadly pneumonia

November 10, 2011
Vaccines against the primary cause of deaths from pneumonia in developing countries could save millions of lives and are highly cost-effective, according to a comprehensive new analysis to be released on Thursday, Nov. 10.

Recommended for you

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.